Literature DB >> 19435416

Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Waleed Mustafa1, Paulo Cesar Maciag, Zhen-kun Pan, Jessica R Weaver, Yuhong Xiao, Stuart N Isaacs, Yvonne Paterson.   

Abstract

Neutralizing antibodies are thought to be required at mucosal surfaces to prevent human papillomavirus (HPV) transmission. However, the potential for cell-mediated immunity in mediating protection against HPV infection has not been well explored. We generated recombinant Listeria monocytogenes (Lm) constructs that secrete listeriolysin O (LLO) fused with overlapping N-terminal (LLO-L1(1-258)) or C-terminal (LLO-L1(238-474)) fragments of HPV type 16 major capsid protein L1 (HPV-16-L1). Oral immunization of mice with either construct induced IFN-gamma-producing CD8+ and CD4+ T cells in the spleen and in the Peyer's patches with the C-terminal construct. Oral immunization with both constructs resulted in diminished viral titers in the cervix and uterus of mice after intravaginal challenge with vaccinia virus expressing HPV-16-L1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435416      PMCID: PMC2763599          DOI: 10.1089/vim.2008.0071

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  56 in total

Review 1.  MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses.

Authors:  E G Pamer; A J Sijts; M S Villanueva; D H Busch; S Vijh
Journal:  Immunol Rev       Date:  1997-08       Impact factor: 12.988

2.  Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Authors:  S Chakrabarti; J R Sisler; B Moss
Journal:  Biotechniques       Date:  1997-12       Impact factor: 1.993

3.  Mucosal vaccination strategies for women.

Authors:  P A Kozlowski; S Cu-Uvin; M R Neutra; T P Flanigan
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

4.  Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines.

Authors:  G Ikonomidis; D A Portnoy; W Gerhard; Y Paterson
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

5.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles.

Authors:  J Zhou; X Y Sun; H Davies; L Crawford; D Park; I H Frazer
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

8.  A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours.

Authors:  Z K Pan; G Ikonomidis; A Lazenby; D Pardoll; Y Paterson
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

9.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

10.  Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas.

Authors:  Vandana A Govan; Edward P Rybicki; Anna-Lise Williamson
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

View more
  6 in total

Review 1.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07

2.  Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.

Authors:  Paul V Johnson; Barbra M Blair; Skye Zeller; Camille N Kotton; Elizabeth L Hohmann
Journal:  Microbiol Immunol       Date:  2011-05       Impact factor: 1.955

3.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Authors:  Xiaofei Yan; Depu Wang; Fengli Liang; Ling Fu; Cheng Guo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Dendritic cell vaccine therapy for colorectal cancer.

Authors:  Amanda L Wooster; Lydia H Girgis; Hayley Brazeale; Trevor S Anderson; Laurence M Wood; Devin B Lowe
Journal:  Pharmacol Res       Date:  2020-12-28       Impact factor: 7.658

5.  Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Authors:  Benjamin Yang; Andrew Yang; Shiwen Peng; Xiaowu Pang; Richard B S Roden; T-C Wu; Chien-Fu Hung
Journal:  Cell Biosci       Date:  2015-06-25       Impact factor: 7.133

Review 6.  Trial Watch: DNA vaccines for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-04-01       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.